DiscoverThe Lancet HIVThird-line therapy
Third-line therapy

Third-line therapy

Update: 2019-09-04
Share

Description

The Lancet HIV Editor Peter Hayward talks to Beatriz Grinsztejn (Evandro Chagas National Institute of Infectious Diseases, Fiocruz, Rio de Janeiro, Brazil) about ACTG A5288, an international, multiarm trial investigating management of second-line treatment failure

Comments 
loading
00:00
00:00
x

0.5x

0.8x

1.0x

1.25x

1.5x

2.0x

3.0x

Sleep Timer

Off

End of Episode

5 Minutes

10 Minutes

15 Minutes

30 Minutes

45 Minutes

60 Minutes

120 Minutes

Third-line therapy

Third-line therapy

The Lancet